The Journal of Stem Cell Biology and Regenerative Sciences (JSCBRS) is committed to maintaining the highest standards of publication ethics, scientific integrity, editorial transparency, and responsible research dissemination. The journal follows internationally accepted publishing guidelines and ethical principles to ensure the credibility, reliability, and quality of all published content. The policies established by the journal are intended to safeguard the integrity of scholarly communication and promote ethical conduct among authors, reviewers, editors, and publishers.

The journal adheres to the ethical recommendations and best practices outlined by organizations such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE), and World Association of Medical Editors (WAME).

Open Access Policy

The Journal of Stem Cell Biology and Regenerative Sciences follows a full open-access publishing model. All articles published in the journal are freely accessible online immediately after publication without subscription barriers or access restrictions. Readers are permitted to read, download, distribute, cite, and share the published content for non-commercial academic and research purposes.

The journal believes that unrestricted access to scientific literature accelerates innovation, encourages interdisciplinary collaboration, and improves the global dissemination of knowledge in stem cell biology and regenerative medicine. Open-access publishing also increases the visibility, reach, and citation potential of scholarly work while supporting equitable access to scientific information across developed and developing nations.

Peer Review Policy

All submitted manuscripts undergo a rigorous double-blind peer-review process to ensure scientific quality, originality, methodological accuracy, and relevance to the journal’s scope. In the double-blind review system, the identities of both authors and reviewers remain confidential throughout the review process.

Each manuscript is initially evaluated by the editorial office for compliance with submission guidelines, ethical standards, plagiarism screening, and scientific suitability. Manuscripts that pass the preliminary assessment are assigned to qualified reviewers with expertise in the relevant field.

Reviewers evaluate manuscripts based on scientific validity, originality, clarity of presentation, methodological rigor, ethical compliance, statistical appropriateness, and clinical or translational significance. Editorial decisions are based solely on scientific merit and reviewer recommendations. The journal reserves the right to accept, reject, or request revisions for any manuscript.

The peer-review process is conducted with fairness, confidentiality, impartiality, and transparency to maintain the integrity of scholarly publishing.

Publication Ethics and Malpractice Statement

The Journal of Stem Cell Biology and Regenerative Sciences is dedicated to preventing publication malpractice and maintaining ethical standards in scientific communication. Authors, editors, reviewers, and publishers are expected to adhere to ethical responsibilities throughout the publication process.

Authors must ensure that submitted work is original, accurately presented, and free from fabrication, falsification, plagiarism, or data manipulation. Simultaneous submission of the same manuscript to multiple journals is strictly prohibited. All contributors who have made significant intellectual contributions must be appropriately acknowledged as authors or contributors.

Editors are responsible for maintaining confidentiality, ensuring unbiased editorial decisions, and preventing conflicts of interest from influencing publication decisions. Reviewers are expected to provide objective, constructive, and confidential evaluations of submitted manuscripts.

Any allegations of ethical misconduct, plagiarism, duplicate publication, image manipulation, citation manipulation, or scientific fraud will be investigated thoroughly following COPE recommendations and internationally accepted ethical procedures.

Plagiarism Policy

The journal maintains a strict anti-plagiarism policy. All submitted manuscripts are screened using plagiarism detection software before peer review and prior to final publication.

Manuscripts containing significant plagiarism, duplicate publication, unattributed content, manipulated citations, or data duplication may be rejected immediately. Authors are responsible for ensuring proper citation and acknowledgment of all previously published work, including text, figures, tables, and datasets.

Self-plagiarism and redundant publication are also considered unethical practices unless appropriately disclosed and justified. If plagiarism is identified after publication, the journal may issue corrections, retractions, or editorial notices depending on the severity of the violation.

Human Subjects and Ethical Approval Policy

Research involving human participants, biological samples, stem-cell-derived tissues, clinical interventions, or patient data must comply with internationally recognized ethical standards and institutional regulations.

Authors must clearly state that ethical approval was obtained from an appropriate Institutional Review Board (IRB), Ethics Committee, or equivalent regulatory authority before commencing the study. The name of the approving institution and approval number should be included within the manuscript.

Studies involving human participants must adhere to the principles outlined in the Declaration of Helsinki and applicable national or international ethical guidelines. Written informed consent must be obtained from all participants or their legal guardians before enrollment in the study.

The journal reserves the right to request supporting ethical documentation during the editorial or peer-review process.

Stem Cell Research and Clinical Trial Policy

Due to the specialized nature of regenerative medicine and stem cell research, the journal requires all studies involving stem cells, cellular therapies, tissue engineering, gene editing, or regenerative interventions to comply with applicable scientific, ethical, and regulatory standards.

Authors must provide detailed information regarding stem cell sourcing, procurement procedures, donor consent, cell characterization, biosafety measures, and laboratory protocols. Clinical trials involving stem-cell-based therapies must include trial registration information from a recognized public clinical trial registry.

Experimental therapies lacking regulatory approval, unsupported clinical claims, or unverified regenerative interventions will not be accepted for publication. The journal strongly supports evidence-based regenerative medicine and responsible scientific reporting.

Animal Research Policy

Studies involving animals must comply with internationally accepted standards for animal welfare, ethical treatment, and laboratory care. Authors must confirm that animal experiments were approved by an institutional animal ethics committee and conducted according to relevant guidelines and regulations.

Manuscripts should include information regarding ethical approval, housing conditions, anesthesia protocols, humane endpoints, and efforts made to minimize animal suffering. Research involving unnecessary harm or unethical treatment of animals will not be considered for publication.

Data Availability and Reproducibility Policy

The journal encourages transparency, reproducibility, and responsible data sharing in scientific research. Authors are encouraged to provide access to raw datasets, supplementary materials, protocols, analytical methods, and supporting information whenever feasible.

Where applicable, authors should include a Data Availability Statement indicating whether data are publicly accessible, available upon request, or subject to restrictions. Studies involving computational biology, bioinformatics, genomics, artificial intelligence, or molecular modeling should provide adequate methodological detail to support reproducibility.

Conflict of Interest Policy

Authors, reviewers, and editors must disclose any financial, institutional, commercial, or personal relationships that could potentially influence the research, peer-review process, or editorial decisions.

Sources of funding, sponsorship, consultancy roles, patents, stock ownership, advisory positions, or commercial affiliations related to the submitted work must be transparently disclosed within the manuscript. Failure to disclose relevant conflicts of interest may result in manuscript rejection, correction, or retraction.

The journal ensures that editorial decisions remain independent and unaffected by financial interests, sponsorships, or commercial relationships.

Copyright and Licensing Policy

All articles published in the Journal of Stem Cell Biology and Regenerative Sciences are licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). This license permits non-commercial sharing, adaptation, distribution, and reproduction of published material provided appropriate credit is given to the original authors and source.

Authors retain copyright ownership of their work while granting the journal the right to publish, archive, and distribute the article. Commercial reuse or reproduction of published material requires prior written permission from the publisher.

Retraction and Correction Policy

The journal is committed to maintaining the integrity of the scholarly record. If significant errors, ethical concerns, fabricated data, plagiarism, or scientific misconduct are identified after publication, the journal may publish corrections, expressions of concern, or retraction notices.

Retraction decisions are made following careful investigation and in accordance with COPE recommendations. Retracted articles will remain accessible online with clear identification of their retracted status to preserve the transparency and integrity of the scientific record.

Archiving Policy

The Journal of Stem Cell Biology and Regenerative Sciences supports long-term digital preservation and archiving of published scholarly content. Published articles may be archived in institutional repositories, academic databases, digital preservation systems, and indexing services to ensure permanent accessibility and scholarly continuity.

Authors are permitted to archive the published version of their articles in institutional repositories, personal websites, and non-commercial academic platforms with appropriate citation and acknowledgment of the journal source.

Advertisement Policy

The journal may publish digital or print advertisements relevant to biomedical sciences, healthcare, laboratory technologies, regenerative medicine, educational services, and academic publishing. Advertisements are managed independently from editorial operations and do not influence editorial decisions or peer-review outcomes.

The journal does not endorse advertised products, services, organizations, or commercial claims. Advertisements containing misleading, deceptive, offensive, discriminatory, or scientifically unsupported information will not be accepted. Promotions related to harmful products, unethical therapies, or unapproved stem-cell-based interventions are strictly prohibited.

Editorial Independence Policy

The editorial board operates independently from sponsors, advertisers, commercial organizations, and external institutions. Editorial decisions are based exclusively on scientific merit, ethical integrity, originality, and relevance to the journal’s aims and scope.

The publisher and editorial team are committed to ensuring transparency, accountability, confidentiality, and fairness throughout the editorial and publication process. External commercial or financial considerations will not influence editorial judgment or publication decisions.

Artificial Intelligence and Generative Technology Policy

The journal recognizes the increasing use of artificial intelligence (AI) and generative technologies in scientific research and manuscript preparation. Authors using AI-assisted tools for language editing, image generation, data analysis, or content refinement must transparently disclose such usage within the manuscript.

AI tools cannot be listed as authors because they cannot assume responsibility for the integrity, originality, or accountability of scientific work. Authors remain fully responsible for all submitted content, including factual accuracy, data interpretation, ethical compliance, and originality.

The use of AI-generated fabricated data, manipulated images, synthetic references, or misleading scientific content is strictly prohibited.

Policy Updates

The Journal of Stem Cell Biology and Regenerative Sciences reserves the right to revise, update, or modify its publication policies, ethical standards, editorial procedures, and author guidelines whenever necessary to align with evolving scientific, ethical, and publishing standards.

Updated policies will be published on the journal website and will become effective immediately upon publication.